Treatment Naïve, Chronic HCV

Peginterferon alfa-2b + RBV vs. Peginterferon alfa-2a + RBV
IDEAL STUDY

**Peginterferon alfa-2b + Ribavirin vs Peginterferon alfa-2a + Ribavirin**

**IDEAL Study: Design**

**Study**
- Randomized comparative trial
- 118 centers in United States

**Subjects**
- N = 3070 with chronic hepatitis C
- All genotype 1 (other genotypes excluded)
- Treatment naïve
- Subjects were 18 years of age or older

**Regimens (Ribavirin Dosed by Weight)**
- Peginterferon alfa-2b: 1.5 µg/kg 1x/week + Ribavirin 800-1400 mg/day*
- Peginterferon alfa-2b: 1.0 µg/kg 1x/week + Ribavirin 800-1400 mg/day*
- Peginterferon alfa-2a: 180 µg 1x/week + Ribavirin 1000-1200 mg/day^*

**Primary Endpoint (Sustained Virologic Response [SVR])**
- SVR = Undetectable serum HCV RNA 24 weeks after 48-week treatments

---

*Ribavirin dosing: 40-65 kg: 800 mg/d; >65-85 kg: 1000 mg/d; >85-105 kg: 1200 mg/d; >105-120 kg: 1400 mg/d

^Ribavirin dosing: < 75 kg: 1000 mg/d; ≥ 75 kg: 1200 mg/d

**Peginterferon alfa-2b + Ribavirin vs Peginterferon alfa-2a + Ribavirin**

**IDEAL Study: Design**

<table>
<thead>
<tr>
<th>Week</th>
<th>0</th>
<th>48</th>
<th>72</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Standard-Dose Peginterferon alfa-2b + Ribavirin**
- N = 1019
- Peginterferon alfa-2b: 1.5 µg/kg 1x/week + Ribavirin: 800-1400 mg/d (by weight)

**Low-Dose Peginterferon alfa-2b + Ribavirin**
- N = 1016
- Peginterferon alfa-2b: 1.0 µg/kg 1x/week + Ribavirin: 800-1400 mg/d (by weight)

**Peginterferon alfa-2a + Ribavirin**
- N = 1035
- Peginterferon alfa-2a: 180 µg 1x/week + Ribavirin: 1000-1200 mg/d (by weight)

Peginterferon alfa-2b + Ribavirin vs Peginterferon alfa-2a + Ribavirin

IDEAL Study: Results

IDEAL Study: Virologic Responses by Treatment Regimen

- Standard-dose Peginterferon alfa-2b + Ribavirin
- Low-dose Peginterferon alfa-2b + Ribavirin
- Peginterferon alfa-2a + Ribavirin

<table>
<thead>
<tr>
<th>Treatment Regimen</th>
<th>End of Treatment Response</th>
<th>Sustained Virologic Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard-dose Peginterferon alfa-2b</td>
<td>53/1019</td>
<td>40/1019</td>
</tr>
<tr>
<td>Low-dose Peginterferon alfa-2b</td>
<td>49/1016</td>
<td>38/1016</td>
</tr>
<tr>
<td>Peginterferon alfa-2a</td>
<td>64/1035</td>
<td>41/1035</td>
</tr>
</tbody>
</table>

Peginterferon alfa-2b + Ribavirin vs Interferon alfa-2a + Ribavirin

IDEAL Study: Results

IDEAL Study: Serious Adverse Event Rates

Peginterferon alfa-2b + Ribavirin vs Peginterferon alfa-2a + Ribavirin
IDEAL Study: Conclusions

**Conclusions:** “In patients infected with HCV genotype 1, the rates of sustained virologic response and tolerability did not differ significantly between the two available peginterferon-ribavirin regimens or between the two doses of peginterferon alfa-2b.”

This slide deck is from the University of Washington’s *Hepatitis C Online* and *Hepatitis Web Study* projects.

**Hepatitis C Online**

www.hepatitisc.uw.edu

**Hepatitis Web Study**

http://depts.washington.edu/hepstudy/

Funded by a grant from the Centers for Disease Control and Prevention.